Marissa S. Pioso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marissa S. Pioso has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed M. Mamdouh
Department of Pharmacy, National University of Singapore, Singapore
35 shared publications - Anthony Letai
Dana-Farber Cancer Institute, Boston, USA
35 shared publications - Binyam Yilma
Tempus AI, Inc, Chicago, IL
35 shared publications - Chuqi Wang
Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore
35 shared publications - David M. Weinstock
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
35 shared publications - Disha Malani
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
35 shared publications
Latest Publications
- 13 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
A syngeneic murine glioma model recapitulates key molecular, immunologic, and functional features of human glioblastoma to enable therapeutic development
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults, characterized by diffuse infiltrative lesions, distinct oncogenic alterations, and a suppressive tumor immune microenvironment (TIME). These traits, however, are not fully recapitulated in current syngeneic murine glioma models, thereby limiting the pre-clinical development of novel therapies. Here we developed murine GBM models with patient-specific mutations that shared striking resemblance with human disease. Mosaic analysis with dual-recombinase mediated cassette exchange (MADR) and CRISPR-Cas9 were leveraged to generate autochthonous tumor models with single-copy somatic transgenesis of murine epidermal growth factor receptor variant III (mEGFRvIII) and loss-of-function mutations commonly observed in GBM. Characterization of a model lacking Pten and Cdkn2a (mEGFRvIII-PC) via histopathologic analyses, functional assays, and single-cell RNA sequencing showed these tumors developed as diffuse, infiltrative lesions with ill-defined margins and a necrotic core. The TIME was primarily comprised of microglia with minimal lymphocyte infiltration, recapitulating patient tumors. Furthermore, these tumors displayed intrinsic resistance to immune checkpoint blockade, potentially due to poor myeloid cell antigen presentation and T cell priming. Additionally, mEGFRvIII-PC cells were the most resistant to antigen-specific T cell-induced cytotoxicity and simultaneously promoted T cell exhaustion, while murine interferon-γ (mIFN-γ) stimulation induced a greater response in vitro with enhanced upregulation of PD-L1 relative to MHC-I. In sum, these findings demonstrate the improved fidelity of the mEGFRvIII-PC model to patient tumors and support its use in developing and refining novel therapeutic paradigms for GBM.
- 13 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
A syngeneic murine glioma model recapitulates key molecular, immunologic, and functional features of human glioblastoma to enable therapeutic development
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults, characterized by diffuse infiltrative lesions, distinct oncogenic alterations, and a suppressive tumor immune microenvironment (TIME). These traits, however, are not fully recapitulated in current syngeneic murine glioma models, thereby limiting the pre-clinical development of novel therapies. Here we developed murine GBM models with patient-specific mutations that shared striking resemblance with human disease. Mosaic analysis with dual-recombinase mediated cassette exchange (MADR) and CRISPR-Cas9 were leveraged to generate autochthonous tumor models with single-copy somatic transgenesis of murine epidermal growth factor receptor variant III (mEGFRvIII) and loss-of-function mutations commonly observed in GBM. Characterization of a model lacking Pten and Cdkn2a (mEGFRvIII-PC) via histopathologic analyses, functional assays, and single-cell RNA sequencing showed these tumors developed as diffuse, infiltrative lesions with ill-defined margins and a necrotic core. The TIME was primarily comprised of microglia with minimal lymphocyte infiltration, recapitulating patient tumors. Furthermore, these tumors displayed intrinsic resistance to immune checkpoint blockade, potentially due to poor myeloid cell antigen presentation and T cell priming. Additionally, mEGFRvIII-PC cells were the most resistant to antigen-specific T cell-induced cytotoxicity and simultaneously promoted T cell exhaustion, while murine interferon-γ (mIFN-γ) stimulation induced a greater response in vitro with enhanced upregulation of PD-L1 relative to MHC-I. In sum, these findings demonstrate the improved fidelity of the mEGFRvIII-PC model to patient tumors and support its use in developing and refining novel therapeutic paradigms for GBM.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 12 shows targeted agents cluster by mechanism of action.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 12 shows targeted agents cluster by mechanism of action.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 6 shows drug response data in AML patient samples at diagnosis and relapse.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 6 shows drug response data in AML patient samples at diagnosis and relapse.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 3 shows MDR mechanisms contribute to drug resistance in AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 3 shows MDR mechanisms contribute to drug resistance in AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 7 shows relapsed or primary refractory AML patients demonstrate reduced ex vivo drug sensitivity compared to diagnosis AML patients.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 7 shows relapsed or primary refractory AML patients demonstrate reduced ex vivo drug sensitivity compared to diagnosis AML patients.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 2 shows RNA-seq signature of drug-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 2 shows RNA-seq signature of drug-resistant AML PDX models.